Fibrobiologics Raises $1.5 M in Direct Offering to Fund Fibroblast‑Based Therapies
Fibrobiologics Inc. raises $1.5 M in a direct offering to fund fibroblast therapies for degenerative disc disease, MS, cancer and more, amid a brief stock dip and cautious market sentiment.
2 minutes to read